hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06345924 id: Meraki_Palliative Care briefTitle: Music Therapy for Cancer Patients(Meraki_PC) acronym: Meraki_Cancer overallStatus: RECRUITING date: 2024-03-01 date: 2024-07 date: 2025-07 date: 2024-04-03 date: 2024-04-15 name: University of Valencia class: OTHER briefSummary: The overall aim of the study is to analyse the impact of a music therapy-based treatment on the emotional well-being and quality of life of cancer patients in palliative care (PC). To this end, the effectiveness and efficiency of a music therapy-based treatment to improve adaptation to illness and psychological well-being in this population will be validated and implemented.
Specifically, the implementation of an individualised treatment programme for palliative care patients will be carried out. conditions: Cancer conditions: Palliative Care studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 80 type: ESTIMATED name: MERAKI_PC measure: Change in Anxiety and Depression Symptomatology (T1, T2 and T4) measure: Change in Quality of Life (T1, T2 and T4) measure: Change in emotional distress (T1, T2, T3 and T4) measure: Change in Social Suport (T1 and T4) measure: Change in Resilience (T1 and T4) measure: Change in Spirituality (T1 and T4) measure: Change Knowledge of the disease (T1 and T4) measure: Barthel Index measure: Pfeiffer Short Form Mental State Questionnaire, SPMSQ measure: Charlson Comorbidity Index (CCI) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Dr. Moliner status: RECRUITING city: Serra state: Valencia country: Spain name: Miguel Fombuena, PhD role: CONTACT email: fombuena_mig@gva.es name: Selene Valero-Moreno, PhD role: SUB_INVESTIGATOR name: Isabel Bellver Vercher role: SUB_INVESTIGATOR name: Ana Alegre Soler role: SUB_INVESTIGATOR name: José Jorge Botella Trellis, Dr. role: SUB_INVESTIGATOR name: Cristina Rocío Espejo Fernández, Dra. role: SUB_INVESTIGATOR name: María Carmen Badía Picazo, Dra. role: SUB_INVESTIGATOR lat: 39.68333 lon: -0.43333 hasResults: False
nctId: NCT06345911 id: NEU-49/899 briefTitle: Do Vacutainers With Animal Characters Reduce Fear and Anxiety? overallStatus: COMPLETED date: 2021-12-01 date: 2022-02-25 date: 2022-03-30 date: 2024-04-03 date: 2024-04-03 name: Burdur Mehmet Akif Ersoy University class: OTHER briefSummary: The study was designed as a randomized controlled experimental research with the purpose of determining the effect of distraction by using vacutainers of three different animal characters. conditions: Procedural Pain conditions: Acute Pain conditions: Fear conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 180 type: ACTUAL name: Experimental group measure: Children's Fear Scale measure: Wong-Baker FACES Pain Rating Scale sex: ALL minimumAge: 4 Years maximumAge: 7 Years stdAges: CHILD facility: Karaman Education and Research Hospital city: Karaman country: Turkey lat: 37.18111 lon: 33.215 hasResults: False
nctId: NCT06345898 id: 2023-1479 briefTitle: Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS) overallStatus: RECRUITING date: 2023-11-17 date: 2026-12-30 date: 2029-12-30 date: 2024-04-03 date: 2024-04-03 name: West China Hospital class: OTHER briefSummary: This trial is to evaluate the safety and efficacy of JWK002 treatment of X-linked retinoschisis(XLRS). This study will enroll subjects aged 5-18 years old to receive a sub-retinal injection of JWK002. conditions: X Linked Retinoschisis studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 9 type: ESTIMATED name: JWK002 measure: Safety(Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events) measure: Best corrected visual acuity (BCVA) measure: Full-field electroretinogram(ff-ERG) measure: Macular structure as assessed by swept source optical coherence tomography measure: Visual field sex: MALE minimumAge: 5 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: West China Hospital status: RECRUITING city: Chengdu state: Sichuan zip: 610023 country: China name: Licong Liang role: CONTACT email: 932968425@qq.com name: Fang Lu role: CONTACT email: lufang@wchscu.cn lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06345885 id: PROPMHP002 briefTitle: Immunogenicity and Safety of One Dose of HPV Vaccine overallStatus: COMPLETED date: 2023-02-23 date: 2024-01-17 date: 2024-01-17 date: 2024-04-03 date: 2024-04-03 name: Xiamen Innovax Biotech Co., Ltd class: INDUSTRY briefSummary: This study will assess the immunogenicity and safety of one dose of Cecolin and one dose of Gardasil conditions: Human Papillomavirus Vaccines studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 200 type: ACTUAL name: HPV vaccine measure: Anti-HPV seropositivity measure: Anti-HPV Seropositivity measure: HPV Antibody Titers measure: Local and Systemic Reactions/Event sex: FEMALE minimumAge: 9 Years maximumAge: 14 Years stdAges: CHILD facility: Fujian Provincial Center for Disease Control and Prevention city: Fuzhou state: Fujian zip: 350012 country: China lat: 26.06139 lon: 119.30611 hasResults: False
nctId: NCT06345872 id: STUDY005883 id: 1R01DA054311 type: NIH link: https://reporter.nih.gov/quickSearch/1R01DA054311 briefTitle: Improving Sleep and Reducing Opioid Use in Individuals With Chronic Pain overallStatus: RECRUITING date: 2024-04 date: 2028-01 date: 2028-07 date: 2024-04-03 date: 2024-04-18 name: University of South Florida class: OTHER name: National Institutes of Health (NIH) name: National Institute on Drug Abuse (NIDA) briefSummary: The goal of this study is to test two behavioral interventions for chronic insomnia in individuals with chronic pain and use prescribed opioid medication to treat their chronic pain. conditions: Chronic Pain conditions: Chronic Insomnia conditions: Opioid Use studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 165 type: ESTIMATED name: CBT-I name: Treatment as usual name: Tapered Withdrawal measure: Change in Insomnia Severity Index measure: Change in Pain Intensity - Daily Electronic Sleep Diaries measure: Change in Wake After Sleep Onset - Daily Electronic Sleep Diaries measure: Change in Sleep Onset Latency- Daily Electronic Sleep Diaries measure: Change in Sleep Efficiency- Daily Electronic Sleep Diaries measure: Change in Fatigue - Daily Electronic Sleep Diaries measure: Change in Sleep and Pain Medication - Daily Electronic Sleep Diaries measure: Change in Perceived Stress Scale measure: Change in Peripheral Arousal measure: Change in Neural Imaging: Structural/Functional MRI/Diffusion Weighted Imaging measure: Change in Thermal Pain Response measure: Change in Opioid Use (Quantitative) measure: Change in Opioid Use (Self-Report) measure: Change in Objective Wake After Sleep Onset (Actigraph) measure: Change in Objective Sleep Onset Latency (Actigraph) measure: Change in Objective Sleep Efficiency (Actigraph) measure: Change in Neural Connectivity: Structural/Functional MRI/Diffusion Weighted Imaging measure: Short Inventory of Problems measure: Change in Pain Catastrophizing Scale measure: Change in 36-Item Short Form Survey (SF-36) measure: Change in Depression (Beck Depression Inventory-II) measure: Change in State-Trait Anxiety Inventory (STAI) measure: Medications/Substances Uses and Dosages measure: Change in Subjective Opioid Withdrawal Scale (SOWS) measure: Change in Opioid Cravings Scale measure: Change in NIH Toolbox sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of South Florida status: RECRUITING city: Tampa state: Florida zip: 33612 country: United States name: Christina S McCrae, PhD role: CONTACT phone: 813-974-1804 email: christinamccrae@usf.edu name: Jasmine L Niazi, MS role: CONTACT phone: (813) 906-0483 email: jlniazi@usf.edu lat: 27.94752 lon: -82.45843 hasResults: False
nctId: NCT06345859 id: UP-23-00467 id: R01MH133842 type: NIH link: https://reporter.nih.gov/quickSearch/R01MH133842 briefTitle: Regulation of Affect and Physiology in Depression acronym: RAPID overallStatus: RECRUITING date: 2024-03-22 date: 2028-04-30 date: 2029-06-30 date: 2024-04-03 date: 2024-04-03 name: University of Southern California class: OTHER name: National Institute of Mental Health (NIMH) briefSummary: Although treatments for depression are effective for many people, not everyone responds to treatment. This lack of treatment response could be due, in part, to the presence of multiple underlying causes of people's depression. This study aims to identify subtypes of depression, based on two factors: how successful people perceive themselves to be at regulating their affect in everyday life; and how much activity in the parasympathetic nervous system increases during moments when people try to regulate. The study involves ambulatory assessment of affect, regulation strategies, and physiological activity in everyday life, in a sample of young adults with remitted major depressive disorder and healthy volunteers. We will study regulation responses in the lab to further determine how subtypes differ in neural, physiological, and behavioral responses. Finally, participants will be randomly assigned to a remote, self-administered biofeedback intervention (vs. control intervention) designed to increase parasympathetic activity and physiological regulation success. While engaging in biofeedback at home for 10 days, participants will simultaneously repeat the ambulatory assessments. This design will allow us to determine the proximal impact of biofeedback on indices of regulation success in everyday life, and whether biofeedback has differential impact on regulation success for different subtypes. conditions: Major Depressive Disorder studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 252 type: ESTIMATED name: Heart rate variability biofeedback measure: Physiological regulation success measure: Average level of heart rate variability measure: Perceived regulation success sex: ALL minimumAge: 18 Years maximumAge: 27 Years stdAges: ADULT facility: University of Southern California status: RECRUITING city: Los Angeles state: California zip: 90089 country: United States name: Umiemah Farrukh role: CONTACT phone: 213-740-4503 email: carlab@usc.edu lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06345846 id: Secondary IOL briefTitle: Stability of Secondary Intraocular Lenses With no Capsular Support overallStatus: ENROLLING_BY_INVITATION date: 2022-12-30 date: 2025-12 date: 2025-12 date: 2024-04-03 date: 2024-04-03 name: Vienna Institute for Research in Ocular Surgery class: OTHER briefSummary: Assessment and differences in the centration, tilt and wobble of two secondary IOLs without capsular support. conditions: Cataract studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 82 type: ESTIMATED name: IFIOL name: SFIOL measure: Centration of the IOL measure: Tilt of the IOL sex: ALL minimumAge: 21 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital, Vienna city: Vienna zip: 1140 country: Austria lat: 48.20849 lon: 16.37208 hasResults: False
nctId: NCT06345833 id: ENT-2024-32847 briefTitle: Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-07-01 date: 2026-07-01 date: 2024-04-03 date: 2024-04-10 name: University of Minnesota class: OTHER briefSummary: Tranexamic acid (TXA) is a fibrinolytic inhibitor which prevents prolonged bleeding by interfering with fibrin clot breakdown by competitively binding to lysine receptors on plasminogen; this prevents the conversion of plasminogen to plasmin. TXA will be applied to a randomly assigned side of the face during facelift surgery. The intervention groups will include 1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine, 3% TXA on TXA-soaked pledgets applied for 10 minutes, and 1% TXA with local plus 3% TXA-soaked pledgets. Each treatment arm will be compared to saline in place of TXA on the contralateral side of the face.
Although TXA has been widely used in surgical fields for decades and is officially recommended by agencies such as ACOG for use during maternal hemorrhage, its current FDA approval only pertains to oral TXA for heavy menstrual bleeding and IV use for patients with hemophilia to prevent or reduce hemorrhage (cite). The main concern with intravenous TXA is the increased risk for the potential formation of blood clots, mainly in patients with clotting disorders, such as Facor V Leiden, and patients on estrogen containing medication. A recent systemic review with metanalysis by Wang et.al contained a total of 2150 patients receiving IV TXA while undergoing plastic surgery concluded that use of IV TXA does not lead to increased adverse events.\[12\] Given the low rate of adverse events while using TXA systemically, this protocol's application of TXA topically and/or locally negates the risk for any potential systemic adverse effects. No systemic adverse effects have been reported in studies examining local TXA in facial plastic surgery to date. conditions: Hemophilia conditions: Hemorrhage conditions: Facelift Surgery studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: 1%Tranexamic acid with standard local name: 3% TXA name: 1% TXA with local plus 3% TXA-soaked pledgets measure: Blood loss measure: adverse effects of TXA rates sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06345820 id: Evolux briefTitle: Comparison of Two Non-diffractive Enhanced Monofocal Intraocular Lenses overallStatus: RECRUITING date: 2023-06-28 date: 2025-06 date: 2025-06 date: 2024-04-03 date: 2024-04-04 name: Vienna Institute for Research in Ocular Surgery class: OTHER briefSummary: Comparison of the clinical performance of two enhanced monofocal IOLs with similar design. conditions: Cataract studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 35 type: ESTIMATED name: Evolux name: Tecnis Eyhance measure: Monocular intermediate visual acuity measure: Monocular distance visual acuity measure: Monocular near visual acuity sex: ALL minimumAge: 21 Years maximumAge: 105 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital, Vienna status: RECRUITING city: Vienna zip: 1140 country: Austria name: Andreas Rotter, MD role: CONTACT phone: 01 91021 phoneExt: 57564 email: office@viros.at name: Manuel Ruiss, MSc role: CONTACT phone: 01 91021 phoneExt: 57564 email: office@viros.at lat: 48.20849 lon: 16.37208 hasResults: False
nctId: NCT06345807 id: 2023-A02617-38 briefTitle: Innovative Care Pathway in Physical Activity and Behavior Change in Coronary Patients Post-cardiac Rehabilitation acronym: APIC overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-11 date: 2026-11 date: 2024-04-03 date: 2024-04-05 name: Elsan class: OTHER briefSummary: The objective of this 18-month research is to show the effectiveness of an individualized physical activity( PA) compared to standard PA management and voluntary PA, to achieve a change in the behavior of the coronary patient. conditions: Individualised Physical Activity Program conditions: Coronary Patient studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: interventional study, randomized in 3 parallel groups, single center, primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 192 type: ESTIMATED name: Individuals activity programs name: activity program name: no Physical Activity program measure: 6 minutes walk test sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06345794 id: 27111 id: J5C-MC-FOAG type: OTHER domain: DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company briefTitle: A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants overallStatus: NOT_YET_RECRUITING date: 2024-04-03 date: 2024-06-17 date: 2024-06-17 date: 2024-04-03 date: 2024-04-03 name: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company class: INDUSTRY name: Eli Lilly and Company briefSummary: The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853) in healthy participants. The study will also evaluate the safety and tolerability of LY4100511 (DICE-853) with itraconazole, fluconazole, and carbamazepine. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 50 type: ESTIMATED name: LY4100511 (DC-853) name: Itraconazole name: Fluconazole name: Carbamazepine measure: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4100511 (DC-853) measure: PK: PK: Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration (AUC[0-t]) of LY4100511 (DC-853) measure: PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY4100511 (DC-853) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: ICON San Antonio Clinical Research Unit city: San Antonio state: Texas zip: 78209 country: United States role: CONTACT phone: 210-283-4500 name: Chinonye Ogbonnaya-Odor role: PRINCIPAL_INVESTIGATOR lat: 29.42412 lon: -98.49363 hasResults: False
nctId: NCT06345781 id: 2174433-1 briefTitle: Abdominal Functional Electrical Stimulation to Improve Bowel Function in Spinal Cord Injury overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-05 date: 2024-04-03 date: 2024-04-03 name: Craig Hospital class: OTHER name: Neuroscience Research Australia briefSummary: The primary objective of this study is to gather information about the effectiveness of abdominal FES to improve bowel management time (BMT) for people with chronic SCI. This study will also evaluate whether abdominal FES can improve: 1) bowel-related quality of life, 2) participant-reported bowel function, 3) bowel management strategy, 4) bladder symptoms, and 5) unplanned hospital admissions. In addition, we will also explore participant perspectives and experiences about the stimulation sessions and use of the device. conditions: Spinal Cord Injuries conditions: Neurogenic Bowel studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: Abdominal Functional Electrical Stimulation measure: Bowel Management Time (BMT) measure: Bowel Management Strategy measure: Stimulation Dose measure: EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Questionnaire measure: International Spinal Cord Society's (ISCoS) International SCI Bowel Function Basic Data Set Questionnaire measure: Visual Analog Scale (VAS) measure: Neurogenic Bladder Symptom Score (NBSS) measure: Intervention Acceptability measure: Intervention Safety sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Craig Hospital city: Englewood state: Colorado zip: 80113 country: United States lat: 39.64777 lon: -104.98776 hasResults: False
nctId: NCT06345768 id: 147258369 briefTitle: The Effect of the Stress Ball Applied Before Colocystectomy Surgery on Patients' Fear, Stress and Comfort. overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-08-01 date: 2024-09-01 date: 2024-04-03 date: 2024-04-03 name: Akdeniz University class: OTHER briefSummary: Cholecystectomy is the most common major abdominal surgical procedure in western countries. Patients may experience fear and anxiety before surgery.
In this study, it is aimed to evaluate the effect of preoperative use of stress ball on patients' fear, stress and comfort in order to determine the effect of stress ball applied before cholecystectomy surgery on patients' surgical fear, stress and comfort. It is thought that the data obtained as a result of the research will provide evidence for the effect of the stress ball, which is a non-pharmacological method used before the procedure, on fear, stress and comfort. conditions: Cholecystitis conditions: Stress conditions: Fear conditions: Comfort studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 90 type: ESTIMATED name: Stress Ball measure: Fear of surgery measure: Fear of surgery measure: Comfort measure: Comfort measure: Stress measure: Stress sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06345755 id: VX23-407-001 briefTitle: A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants overallStatus: RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-03 date: 2024-04-26 name: Vertex Pharmaceuticals Incorporated class: INDUSTRY briefSummary: The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants. conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD) studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 95 type: ESTIMATED name: VX-407 name: Placebo name: Midazolam measure: Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) measure: Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) measure: Part C: Maximum Observed Plasma Concentration (Cmax) of MDZ in Absence and Presence of VX-407 measure: Part C: Area Under the Concentration Versus Time Curve (AUC) of MDZ in Absence and Presence of VX-407 measure: Part A: Maximum Observed Plasma Concentration (Cmax) of VX-407 measure: Part B: Maximum Observed Plasma Concentration (Cmax) of VX-407 measure: Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-407 measure: Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-407 measure: Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: ICON Lenexa status: RECRUITING city: Lenexa state: Kansas zip: 66219 country: United States lat: 38.95362 lon: -94.73357 hasResults: False
nctId: NCT06345742 id: ATADEK-2023-10/396 briefTitle: The Effect of Parental Participation on Newborn Comfort During Diaper Care overallStatus: RECRUITING date: 2023-12-19 date: 2025-02-01 date: 2025-02-01 date: 2024-04-03 date: 2024-04-03 name: Acibadem University class: OTHER briefSummary: It was aimed to determine the effect of parental participation on newborn comfort during diaper care practice in preterm infants.